ProLynx specializes in advanced biopharmaceutical technologies, focusing on the development of innovative drug delivery systems. Their proprietary platform enhances the therapeutic efficacy of biologics by improving their pharmacokinetics and reducing immunogenicity. This technology allows for the creation of long-acting formulations that can significantly extend the duration of action for various therapeutic agents, thereby improving patient compliance and treatment outcomes.

In addition to their drug delivery systems, ProLynx employs cutting-edge science in the design of their products, utilizing a combination of protein engineering and formulation science. Their approach emphasizes the importance of optimizing the stability and solubility of biologics, which is crucial for maintaining their effectiveness. By leveraging these technologies, ProLynx aims to address critical challenges in the biopharmaceutical industry, ultimately leading to more effective and safer treatment options for patients.

United States

ProLynx Inc is a clinical-stage biopharmaceutical company specializing in the development of novel long-acting therapeutics. We are leveraging our drug delivery platform technology to enhance the delivery, half-life, efficacy, and safety of drugs. 

ProLynx's technology enables predictable and controllable half-life extension of drugs – including peptides, proteins and small molecules – using nano, macromolecular and fix supports (SC, IV & IT injectables, implants, and others). This technology improves the pharmacokinetics, pharmacodynamics, and reduced dosing frequency compared to conventional delivery methods.

ProLynx

Company Details